A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.
about
Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigenPhase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancerStructural Insights into the Inhibition of Wnt Signaling by Cancer Antigen 5T4/Wnt-Activated Inhibitory Factor 1Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epitheliaCD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer.First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.The expression of 5T4 antigen in colorectal and gastric carcinomaEvaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.Trophoblast glycoprotein: possible candidate mediating podocyte injuries in glomerulonephritisMetastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells.An update on TroVax for the treatment of progressive castration-resistant prostate cancerControl of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma.Investigation of expression of 5T4 antigen in cervical cancerImmunohistological distribution of 5T4 antigen in normal and malignant tissuesCD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft modelA phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy.Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen.5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.Vaccine therapy for renal cancer.Kit K641E oncogene up-regulates Sprouty homolog 4 and trophoblast glycoprotein in interstitial cells of Cajal in a murine model of gastrointestinal stromal tumoursNaptumomab estafenatox: a new immunoconjugate.5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.TroVax(®) vaccine therapy for renal cell carcinoma.Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4.Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxinEvolving Strategies for Target Selection for Antibody-Drug Conjugates.5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.High throughput analysis of proteins associating with a proinvasive MT1-MMP in human malignant melanoma A375 cells.Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer.In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies.Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins.Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
P2860
Q24534036-7B17DC27-18FE-4DCE-B94E-81E117747C0DQ24645548-3518B35E-55D7-4FA4-92D8-DD1DB308F5D8Q27681929-A5BA364A-1B22-441F-9FB0-83F9A2EBEDE6Q28513567-3086634C-4AC3-4F28-9B7C-74AF9BBF7583Q33268298-8084688E-AB80-4EAA-8825-3ACC4EF0948AQ33438286-9C5FBFCB-90D4-4285-9D0E-16A6CE9C57D1Q33550832-BB08D84A-6CE7-4C6F-A16E-F655B165602DQ34257785-0B6F70B2-3580-4FF9-BD06-A6FA8547AF54Q34260594-31C7134B-DC9C-4D39-B95C-72DAC2B7840EQ34354544-94459C8C-CFB7-47FA-9F1B-1B2F5204F144Q34405136-405A276F-100E-4EAE-94DE-15E8C002902BQ35050205-63DE1AE8-EF16-4CB5-81E5-34E09DD1CCC3Q35149457-7DCB3261-C49E-465E-8E47-138BCFCE4BE1Q35978519-DBF1B195-3C81-46DC-91DF-753C663C0BCCQ35981452-3390732F-C1AA-4A40-B31D-FC5F1973B1A1Q35981522-337F2CF2-1630-49B5-99DC-CBD5B68550F8Q36177214-CF0BC2C4-75C7-44B5-B5AB-34766B7E7942Q36609877-2C9BE80B-EFEC-461C-B017-442C8729D55DQ36615307-F9B66819-4876-4024-AA78-1D02E98907B1Q36623092-6E0E76AE-C8FC-4CDA-9F86-C6F398F04580Q36922276-C9530BAA-4A0B-4AAE-B060-1BF76740F29DQ37259586-2686A121-5090-4B3F-9DC4-5366E7298936Q37310645-9CD281EA-1762-40C6-BA06-1BFE03547CAEQ37669341-4B621B4D-5195-42AE-B8AD-C20CB4450DFBQ37678414-F36020FB-5D67-420E-BB57-2FD309C9BBFEQ37965748-DFCC17CD-BA9B-438B-8CDD-B880112CBECFQ38123176-967C07AE-219F-44E7-9C33-2BD1770F240EQ38180315-1CFB6B54-778E-4058-A094-0F6AC7F91442Q38920359-96F08E52-2A2D-4E45-94E6-CDEB7CBB0886Q38984929-C3F578ED-2D79-4E93-9CAA-1F05A95663DDQ39774023-7B0E1A4E-D2F5-4D52-A43C-3761D5841B87Q39853178-07AFF86E-C47A-49F0-BF01-256CF682BEF0Q40357390-58C03B42-7996-49F1-9811-65C4040D735DQ40445773-AA17E5F8-6E6B-418F-BE94-8A0CD54C03C3Q40696514-0AAC4081-CF0A-483B-B0C0-BC95CC92669BQ40732932-9C2ED978-DC56-4CE2-927B-DCCA7EA49ACDQ42638914-C4D2C2B5-E3C0-467A-AF5E-B1FE643B146EQ45025116-A9D0D4CC-451D-4521-ACC0-FAA978FC1D06Q45422169-58616CF4-2565-409F-85F6-3461A891DBB3Q47630188-04D5959D-0D05-49C3-8260-A9524D3345CC
P2860
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.
@en
type
label
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.
@en
prefLabel
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.
@en
P2860
P356
P1476
A 72 kD trophoblast glycoprotein defined by a monoclonal antibody.
@en
P2860
P2888
P304
P356
10.1038/BJC.1988.53
P407
P577
1988-03-01T00:00:00Z
P5875
P6179
1015088816